[go: up one dir, main page]

BR112019007309A2 - anticorpos anti-c1s e métodos de uso dos mesmos - Google Patents

anticorpos anti-c1s e métodos de uso dos mesmos

Info

Publication number
BR112019007309A2
BR112019007309A2 BR112019007309A BR112019007309A BR112019007309A2 BR 112019007309 A2 BR112019007309 A2 BR 112019007309A2 BR 112019007309 A BR112019007309 A BR 112019007309A BR 112019007309 A BR112019007309 A BR 112019007309A BR 112019007309 A2 BR112019007309 A2 BR 112019007309A2
Authority
BR
Brazil
Prior art keywords
antibodies
present disclosure
disclosure provides
methods
nucleic acids
Prior art date
Application number
BR112019007309A
Other languages
English (en)
Inventor
Parry Graham
E Stagliano Nancy
Panicker Sandip
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of BR112019007309A2 publication Critical patent/BR112019007309A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente descrição refere-se a anticorpos que ligam especificamente o componente da via do complemento c1s. a presente descrição fornece ácidos nucleicos compreendendo sequências de nucleotídeo que codificam os anticorpos anti-c1s; e células hospedeiras compreendendo os ácidos nucleicos. a presente descrição fornece composições compreendendo os anticorpos anti-c1s. a presente descrição fornece métodos de uso dos anticorpos anti-c1s.
BR112019007309A 2016-10-12 2017-10-12 anticorpos anti-c1s e métodos de uso dos mesmos BR112019007309A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12
PCT/US2017/056349 WO2018071676A1 (en) 2016-10-12 2017-10-12 Anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112019007309A2 true BR112019007309A2 (pt) 2019-07-02

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007309A BR112019007309A2 (pt) 2016-10-12 2017-10-12 anticorpos anti-c1s e métodos de uso dos mesmos

Country Status (24)

Country Link
US (2) US20200048332A1 (pt)
EP (1) EP3525583B1 (pt)
JP (3) JP7069138B2 (pt)
KR (2) KR102638884B1 (pt)
CN (2) CN116554320A (pt)
AR (1) AR110677A1 (pt)
AU (2) AU2017341766A1 (pt)
BR (1) BR112019007309A2 (pt)
CA (1) CA3040253A1 (pt)
CL (1) CL2019000975A1 (pt)
CO (1) CO2019004741A2 (pt)
CR (1) CR20190223A (pt)
DO (1) DOP2019000085A (pt)
EA (1) EA201990884A1 (pt)
EC (1) ECSP19033211A (pt)
IL (2) IL308156A (pt)
MX (2) MX2019004259A (pt)
PE (1) PE20191031A1 (pt)
PH (1) PH12019500789A1 (pt)
SG (1) SG11201903012RA (pt)
TN (1) TN2019000109A1 (pt)
TW (3) TWI773695B (pt)
WO (1) WO2018071676A1 (pt)
ZA (1) ZA201902247B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
SG11201707886WA (en) 2015-04-06 2017-10-30 True North Therapeutics Inc Humanized anti-c1s antibodies and methods of use thereof
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
MX2022013135A (es) * 2020-04-20 2022-11-10 Genzyme Corp Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos.
IL296579A (en) * 2020-04-22 2022-11-01 Chemomab Ltd Antibody against ccl24 for use in a treatment method
JP2023527684A (ja) * 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド 神経疾患を治療するための補体成分ｃ１ｓ阻害剤、並びにそれを使用する関連組成物、システム及び方法
EP4193153A1 (en) * 2020-08-06 2023-06-14 Bioverativ USA Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
JP2024518844A (ja) 2021-05-20 2024-05-07 ダイアンサス セラピューティクス オプコ， インコーポレイテッド Ｃ１ｓに結合する抗体およびその使用
CN117642431B (zh) * 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途
US20240401082A1 (en) 2023-03-16 2024-12-05 Genzyme Corporation Treatment of Dry Age-Related Macular Degeneration

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
ES2328585T3 (es) 1993-10-25 2009-11-16 Canji, Inc. Vector de adenovirus recombinante y metodo de utilizacion.
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DK0904392T3 (da) 1996-10-17 2001-04-30 Oxford Biomedica Ltd Retrovirale vektorer
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
EP2221315A1 (en) * 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
SG172616A1 (en) * 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007004670A1 (ja) 2005-07-05 2007-01-11 Kaneka Corporation メタクリル系樹脂組成物
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
WO2009020640A2 (en) * 2007-08-08 2009-02-12 Swarmcast, Inc. Media player plug-in installation techniques
SG10201610247QA (en) * 2008-12-03 2017-02-27 Genmab As Antibody variants having modifications in the constant region
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2833908C (en) 2010-04-23 2021-02-09 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
EP2912065A4 (en) * 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
GB2509260B (en) * 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
WO2014119969A1 (ko) * 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
WO2014189378A1 (en) * 2013-05-23 2014-11-27 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof
HK1225678A1 (zh) * 2013-07-09 2017-09-15 安尼艾克松股份有限公司 抗-補體因子c1q抗體及其應用
SG11201707886WA (en) * 2015-04-06 2017-10-30 True North Therapeutics Inc Humanized anti-c1s antibodies and methods of use thereof

Also Published As

Publication number Publication date
CL2019000975A1 (es) 2019-10-04
CN116554320A (zh) 2023-08-08
JP2020502996A (ja) 2020-01-30
WO2018071676A1 (en) 2018-04-19
MX2019004259A (es) 2019-09-27
AR110677A1 (es) 2019-04-24
CR20190223A (es) 2019-08-21
TW201821437A (zh) 2018-06-16
AU2017341766A1 (en) 2019-05-23
TWI846007B (zh) 2024-06-21
IL265957A (en) 2019-05-30
MX2024008202A (es) 2024-07-15
CN110300520B (zh) 2022-10-04
JP2024038319A (ja) 2024-03-19
JP2022105114A (ja) 2022-07-12
CN110300520A (zh) 2019-10-01
TN2019000109A1 (en) 2020-10-05
PH12019500789A1 (en) 2019-07-29
IL265957B1 (en) 2023-12-01
JP7069138B2 (ja) 2022-05-17
TW202246327A (zh) 2022-12-01
IL265957B2 (en) 2024-04-01
KR102638884B1 (ko) 2024-02-22
TWI773695B (zh) 2022-08-11
EP3525583A4 (en) 2020-06-10
DOP2019000085A (es) 2019-07-31
EP3525583A1 (en) 2019-08-21
IL308156A (en) 2023-12-01
JP7420864B2 (ja) 2024-01-23
TW202434298A (zh) 2024-09-01
CA3040253A1 (en) 2018-04-19
AU2022205174A1 (en) 2022-09-29
US20200048332A1 (en) 2020-02-13
SG11201903012RA (en) 2019-05-30
ECSP19033211A (es) 2019-07-31
KR20240025715A (ko) 2024-02-27
PE20191031A1 (es) 2019-08-05
CO2019004741A2 (es) 2019-07-31
ZA201902247B (en) 2024-07-31
US20240076363A1 (en) 2024-03-07
KR20190082783A (ko) 2019-07-10
EP3525583B1 (en) 2025-07-23
EA201990884A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos
BR112017021289A2 (pt) anticorpos anti-c1s humanizados e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018007017A2 (pt) polipeptídeos
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2020000937A1 (es) Anticuerpo multiespecífico.
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112017003582A2 (pt) anticorpos, composições e usos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
CL2016000358A1 (es) Vacuna para adenovirus aviar
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112017008867A2 (pt) inibidores de proteína quinases
BR112016004450A2 (pt) métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
BR112018007173A2 (pt) métodos e composições para prevenir ou tratar câncer

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 1/02 , A61B 5/055 , A61K 39/395

Ipc: C07K 16/18 (2006.01), A61K 39/395 (2006.01), A61B

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]